• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis)

  • Profile

Profile

Contact Information

Contact: Pfizer
Website: www.vyndamax.com; www.vyndamax.com/vyndaqel

Currently Enrolling Trials

    Show More

    General Information

    Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) are oral transthyretin stabilizers. Vyndamax was developed for patient convenience. Vyndaqel and Vyndamax are not substitutable on a per milligram basis.

    Vyndaqel and Vyndamax are specifically indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

    Vyndaqel and Vyndamax are supplied as capsules for oral administration. The recommended dose is either Vyndaqel 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or Vyndanmax 61 mg (one 61-mg tafamidis capsule) orally once daily.

    Mechanism of Action

    Vyndaqel (tafamidis meglumine) is an oral transthyretin stabilizer that selectively bind to transthyretin, stabilizing the tetramer of the transthyretin transport protein and slowing the formation of amyloid that causes ATTR-CM.

    Side Effects

    In clinical trials, the frequency of adverse events in patients treated with Vyndaqel was similar to placebo, and similar proportions of Vyndaqel-treated patients and placebo-treated patients discontinued the study drug because of an adverse event.

    Clinical Trial Results

    The FDA approval was based on a multicenter, international, randomized, double-blind, placebo-controlled study in 441 patients with wild type or hereditary ATTR-CM. Patients were randomized in a 1:2:2 ratio to receive Vyndaqel 20 mg (n=88), Vyndaqel  80 mg (administered as four 20-mg Vyndaqel capsules) (n=176), or matching placebo (n=177) once daily for 30 months, in addition to standard of care (e.g., diuretics). Treatment assignment was stratified by the presence or absence of a variant TTR genotype as well as baseline disease severity (NYHA Class). Transplant patients were excluded from this study. The analysis demonstrated a significant reduction in all-cause mortality and frequency of cardiovascular-related hospitalizations in the pooled Vyndaqel 20 mg and 80 mg arms versus placebo. Analysis of the individual components of the primary analysis (all-cause mortality and cardiovascular-related hospitalizations) also demonstrated significant reductions for Vyndaqel versus placebo.

    Approval Date: 2019-05-01
    Company Name: Pfizer
    Back to Listings

    Upcoming Events

    • 15Sep

      Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

    • 21Sep

      The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

    • 16Oct

      WCG MAGI's Clinical Research Conference 2022 West

    • 16Nov

      17th Annual FDA Inspections Summit

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Options-360x240.png

      Cancer Patients Signal Interest in Less Travel, More Remote Trial Options

    • SurveywBlueBackground-360x240.png

      New Study Shows Trends in Funding, Racial Balance Amidst COVID-19

    • Complexity-360x240.png

      Rising Trial Complexities Create More Payment Problems, Frustrations for Sites

    • Challenge-360x240.png

      BYOD Trials Growing in Popularity, But Unique Tech Challenges Remain

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing